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Abstract
Background: Infection risks vary among individuals and between populations. Here we present information on the
seroprevalence of 13 common infectious agents in a San Antonio-based sample of Mexican Americans. Mexican
Americans represent the largest and most rapidly growing minority population in the U.S., and they are also
considered a health disparities population.
Methods: We analyzed 1227 individuals for antibody titer to Chlamydophila pneumoniae, Helicobacter pylori,
Toxoplasma gondii, cytomegalovirus, Epstein-Barr virus, herpes simplex virus-1, herpes simplex virus-2 (HSV-2),
human herpesvirus-6 (HHV-6), varicella zoster virus (VZV), adenovirus-36, hepatitis A virus, and influenza A and B.
Seroprevalence was examined as a function of sex, age, household income, and education.
Results: Seroprevalence estimates ranged from 9% for T. gondii to 92% for VZV, and were similar in both sexes
except for HSV-2, which was more prevalent in women. Many pathogens exhibited a significant seroprevalence
change over the examined age range (15-94 years), with 7 pathogens increasing and HHV-6 decreasing with age.
Socioeconomic status significantly correlated with serostatus for some pathogens.
Conclusions: Our findings demonstrate substantial seroprevalence rates of these common infections in this sample
of Mexican Americans from San Antonio, Texas that suffers from high rates of chronic diseases including obesity
and type-2 diabetes.
Background
The presence of antibodies specific to a given pathogen is
indicative of a current or previous exposure to an infec-
tious agent either through infection or vaccination. Hence,
seroprevalence is an often-used measure of the frequency
of common infections in a population. Seroprevalence for
many agents is noted to increase with age, most likely due
to increased opportunity for exposure over the course of
an individual’s lifetime. In some instances, such as for
herpes simplex virus type 2 in the general U.S. population,
seroprevalence is unequal between the sexes [1], but more
often there is no sex bias. Other factors, including socioe-
conomic status, household crowding, breastfeeding
practices, food-production practices, and level of parental
education, have also been shown to influence the seropre-
valence of particular pathogens within a population [2-6].
Thus, prevalence of exposure to a particular pathogen, as
reflected in seroreactivity, tends to vary between and
within populations and is often associated with disparities
in socioeconomic status and differences in ethnic back-
ground [2,7,8].
T h e r ei sag r o w i n gb o d yo fe v i d e n c es u g g e s t i n gt h a t
inflammation associated with persistent infection may
contribute to the development of cardiovascular disease
and other chronic diseases of aging [9-11]. In certain
cases, particular pathogens have been linked to chronic
disease. For example, infection with Chlamydophila
pneumoniae (formerly Chlamydia pneumoniae) has been
found to be associated with atherosclerosis, coronary
heart disease, myocardial infarction, and general risk of
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including Helicobacter pylori, cytomegalovirus, Epstein-
Barr virus, hepatitis A virus, and herpes simplex 1 virus
have also been identified as potentially contributing to
cardiovascular disease, although there are discrepancies
between studies [14-17]. It has also been speculated that
pathogen burden (i.e., the number of different infections
in an individual) may contribute to atherosclerosis or
other chronic disease. Studies have shown an association
between pathogen burden and C-reactive protein levels,
clinical disease outcomes, and overall risk of cardiovascu-
lar disease [18-21].
Mexican Americans have been shown, in general, to
have unequal access to health care and to suffer greater
morbidity and mortality due to a variety of both infec-
tious and chronic diseases, including heart disease and
diabetes, in comparison with the overall U.S. population
[22]. Focusing on this “health disparities population” is
even more crucial because Hispanics are the largest and
fastest growing minority population in the U.S., surpass-
ing 45 million individuals and comprising 15% of the
total population, and Mexican Americans constitute the
majority (> 60%) of this group [23].
We have here specifically investigated Mexican Ameri-
cans from around San Antonio, Texas, which may not
be representative of all US-based Hispanics. As some of
the relatives of study participants resided in Monterrey,
Nuevo León, Mexico, we compare the seroprevalence
rates between the two locations (U.S. versus Mexico).
We report the seroprevalence, as a function of sex, age,
household income, and education level, in this sample
of Mexican Americans for thirteen relatively common
pathogens, which were chosen based on three criteria: i)
reported moderate to high frequency in the general U.S.
population, ii) relative ease of transmission (i.e., thought
to be primarily acquired through casual person-to-per-
son contact or through respiratory secretions, at least
for most of the investigated pathogens), and, iii) sus-
pected involvement in cardiovascular disease or other
chronic disorders. Typical infections with most of these
agents cause subclinical or relatively mild symptoms,
although some can cause severe manifestations.
Methods
Participants
Individuals participating in this study included 1,227
members of randomly ascertained, extended Mexican
American families from San Antonio, TX, and the sur-
rounding region [24] (Table 1). The subjects were
recruited during the years 1991-1995 for participation in
the San Antonio Family Heart Study (SAFHS), which
seeks to identify genetic risk factors for cardiovascular
disease. In addition, another 147 individuals residing in
Monterrey, Nuevo León, Mexico, were recruited to
participate in the study because they are family mem-
bers of participants from San Antonio, and they are
required to build the multigenerational genealogies of
the study participants. Participants range in age from 15
to 95 years. Study protocols were approved by The Uni-
versity of Texas Health Science Center at San Antonio
and all participants signed statements of informed con-
sent. Many types of data were collected, including infor-
mation on sex, age, education level, household income,
and location of residence.
Serology
Following an overnight fast, blood samples were collected
from participants using EDTA vacutainers at the time of
recruitment (1991-1995). At that time, frozen plasma ali-
quots were obtained as previously described [25] and
stored at -80°C. These archived samples were thawed just
prior to use for antibody determinations, which were per-
formed during 2008-2010. Of the infectious pathogens
examined in this study, two are bacterial, C. pneumoniae
and H. pylori; one, Toxoplasma gondii, is a protozoan; and
the remaining pathogens are viruses. The viral pathogens
include six members of the herpes virus family: cytomega-
lovirus (CMV); Epstein-Barr virus (EBV); herpes simplex
type I virus (HSV-1); herpes simplex type II virus (HSV-2);
Table 1 Participant characteristics
Characteristic Value (percent)
Sex
Male 482 (39.3%)
Female 745 (60.7%)
Age
Age range 15-94 years
Mean age 39 years
Education*
Elementary school (1-8 years) 329 (27.9%)
Some high school (9-11 years) 324 (27.5%)
High school graduation (12 years) 370 (31.4%)
Some college (> 12 years) 157 (13.3%)
Monthly Household Income†
Under $500 181 (16.2%)
$500-$749 159 (14.2%)
$750-$999 143 (12.8%)
$1000-$1249 171 (15.3%)
$1250-$1499 117 (10.5%)
$1500-$1999 123 (11.0%)
$2000-$2999 127 (11.4%)
$3000 and above 95 (8.5%)
Residence
Texas 1211(98.7%)
Other US location 16 (1.3%)
*Information available for 1180 participants
†Information available for 1116 participants
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Page 2 of 10human herpesvirus 6 (HHV-6); and varicella zoster virus
(VZV). The remaining viruses are adenovirus 36 (Ad-36);
hepatitis A virus (HAV); influenza A virus; and influenza
B virus. All of these pathogens typically induce measure-
able humoral responses in exposed immune competent
individuals. Although vaccinations may affect pathogen
seroprevalence rates, in this study population immuniza-
tions were only available for influenza A and B when these
samples were collected, so all other seroprevalence rates
directly reflect current or prior exposure to the relevant
pathogens.
Commercially available ELISA kits were used to deter-
mine immunoglobulin G (IgG) antibody titers to:
C. pneumoniae (Bioclone Australia Pty Ltd., Marrickville
NSW Australia); H. pylori and CMV (Inverness Medical
Professional Diagnostics, Palatine, IL); T. gondii,E B V
(specifically to EBV nuclear antigen [EBNA]), VZV,
influenza A, and influenza B (IBL America, Minneapolis,
MN); HSV-1 and HSV-2 (Focus Diagnostics Inc., Phila-
delphia, PA); HAV (Bio-Rad Laboratories, Redmond,
WA); and HHV-6 (Advanced Biotechnologies, Rockville,
MD). A published serum neutralization test was utilized
for measuring Ad-36 antibodies [26].
For commercial ELISA assays, the manufacturers’
instructions were used to determine seropositive/serone-
gative status according to the following absorbance values:
seronegative if ≤ 0.9; indeterminate if > 0.9 and < 1.1; and
seropositive if ≥1.1. The cut-off value for T. gondii seropo-
sitivity was equivalent to 10 IU/ml. Ad-36 analyses were
run in duplicate, with specimens assigned as seropositive if
both replicates had neutralization titres ≥1:8, otherwise
they were considered to be seronegative.
Statistical analysis
Because this study included relatives, we used a variance
components (VC) model implemented in a software pack-
age, SOLAR [27], that is explicitly designed for analysis of
pedigree data. The non-independence of relatives due to
the additive effects of genes in aggregate was properly
taken into account using a random effects kinship para-
meter, which absorbs phenotypic (co-)variation due to the
expected overall genetic similarity among relatives [28].
For analysis of dichotomous phenotypes (such as seroposi-
tive versus seronegative status), a liability threshold model
(i.e., a theoretical and unobservable quantitative liability
was assumed to underlie the dichotomous phenotype,
with those individuals exceeding a threshold value consid-
ered to be affected) was used within the VC framework
[29]. The effects of sex, age, household income, education,
and location (U.S. or Mexico) on serostatus of the patho-
gens were assessed by maximum likelihood methods using
a fixed effect linear regression model within the mixed
model framework. Those variables not of primary interest
in an analysis were treated as nuisance parameters,
including sex, age, age
2, sex by age, and sex by age
2 (for
assessing the effects of income, education, and location on
serostatus); age and age
2 (for assessing sex effects); and sex
(for assessing effects due to age). The resulting p-values
were adjusted for multiple testing (i.e., pathogens investi-
gated) using the Sidàk approximation [30].
Results
This study is based on 1, 227 Mexican American indivi-
duals taking part in the San Antonio Family Heart Study
(SAFHS) [24]. They are members of extended families that
were ascertained irrespective of any disease status. An
overview of the relevant characteristics of the study parti-
cipants is given in Table 1. The SAFHS also includes
another 147 individuals living in Mexico (largely in Mon-
terrey, Nuevo León, approximately a five hour drive by car
from San Antonio), who were recruited to participate in
the study because they are relatives of study participants
from San Antonio. As the first step in our analyses, we
determined whether there were differences in pathogen
seroprevalence estimates between the 1,227 individuals liv-
ing in the U.S. (Table 2) and the 147 participants from
Mexico (Additional File 1: Table S1). Seroprevalence rates
for six of the 13 pathogens exhibited significant differences
in sex- and age-adjusted seroprevalence by location, after
correcting for multiple testing (i.e., examined pathogens)
(Table 3). For example, HAV seroprevalence was higher in
Mexico (p = 2.3 × 10
-7), while influenza B seroprevalence
was significantly lower (p = 4.5 × 10
-5). As the sample
from Mexico is relatively small and many factors may con-
tribute to different seroprevalence rates between both
countries, we decided to exclude individuals from Mexico
from subsequent analyses, which focused only on the 1,
227 participants living in the U.S.
The overall seroprevalence estimates by sex and age cate-
gory for each pathogen are presented in Table 2. The
pathogen with the highest seroprevalence estimate in the
Mexican American study population was VZV, at 92%
(98% including the indeterminate samples among the sero-
positive ones). The overall seroprevalence rates of other
herpesviruses were 82% for HSV-1, 82% for HHV-6, 55%
for CMV, 46% for EBV, and 22% for HSV-2. The seropre-
valence rates for the other viruses were 77% for influenza
A, 58% for influenza B, 73% for HAV, and 13% for Ad-36.
Of the bacterial pathogens, C. pneumoniae had a high ser-
oprevalence rate (86%), and H. pylori had a seroprevalence
of 57%. T. gondii displayed the lowest seroprevalence rate
among the pathogens tested (9%). Although vaccines cur-
rently exist for influenza, VZV, and HAV, only influenza
vaccines were available at the time of collection of blood
specimens for this study (1991-1995).
For the majority of pathogens in this study, seropreva-
lence was similar between the sexes (Tables 2 and 3).
However, a significant difference in seroprevalence was
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Page 3 of 10Table 2 Seroprevalence by sex and age
Sex and Age
Categories
count Cp Hp Tg CMV EBV HSV-1 HSV-2 HHV-6 VZV Ad- 36 HAV IA IB
Females
< 20 71 84.5 31.0 1.4 26.8 40.8 80.3 7.0 93.0 95.8 14.1 32.4 77.5 60.6
20-29 188 85.1 49.5 8.5 38.3 46.3 78.2 17.6 87.8 92.6 12.8 63.3 71.3 51.6
30-39 149 83.9 53.7 6.0 63.8 47.0 83.2 21.5 81.9 91.9 13.4 78.5 69.1 56.4
40-49 165 81.2 60.0 6.1 72.1 42.4 82.4 32.1 75.8 88.5 10.9 81.2 73.9 52.7
50-59 86 93.0 72.1 11.6 76.7 47.7 86.0 34.9 74.4 91.9 16.3 95.3 69.8 46.5
60-69 49 77.6 79.6 16.3 75.5 36.7 83.7 44.9 67.3 85.7 20.4 98.0 85.7 69.4
≥70 37 81.1 81.1 27.0 91.9 35.1 89.2 37.8 64.9 97.3 18.9 86.5 89.2 59.5
subtotal 745 84.2 57.0 8.6 59.3 44.0 82.1 25.4 80.4 91.5 13.8 74.5 73.7 54.6
Males
< 20 75 88.0 32.0 4.0 28.0 45.3 69.3 5.3 90.7 94.7 10.7 29.3 81.3 62.7
20-29 122 81.1 45.9 2.5 32.8 54.1 78.7 13.1 93.4 92.6 17.2 59.8 78.7 62.3
30-39 85 84.7 67.1 10.6 52.9 47.1 82.4 21.2 84.7 88.2 14.1 78.8 80.0 68.2
40-49 89 92.1 67.4 9.0 61.8 56.2 87.6 13.5 75.3 95.5 14.6 86.5 80.9 62.9
50-59 56 89.3 67.9 19.6 64.3 35.7 85.7 16.1 78.6 91.1 5.4 91.1 83.9 44.6
60-69 29 100 65.5 17.2 75.9 48.3 82.8 27.6 72.4 100 13.8 96.6 86.2 58.6
≥70 26 100 84.6 38.5 73.1 65.4 88.5 38.5 61.5 96.2 3.8 92.3 84.6 76.9
subtotal 482 88.0 57.3 10.2 49.4 50.0 81.1 16.0 83.4 93.2 12.9 71.0 81.1 62.0
Overall
(counting
indeterminates
as
seropositives)
1227 85.7
(91.2)
57.1
(61.3)
9.2
(12.0)
55.4
(61.8)
46.4
(69.8)
81.7
(83.2)
21.7
(22.9)
81.6
(88.9)
92.2
(98.1)
13.4
(13.4)
73.1
(73.2)
76.6
(89.2)
57.5
(76.5)
Cp = C. pneumoniae; Hp = H. pylori; Tg = T. gondii; IA = Influenza A; IB = Influenza B
Table 3 Predictors of serostatus
Pathogen Location
regression coefficient*
(p-value)
Sex
regression coefficient†
(p-value)
Age
regression coefficient
(p-value)
Education
regression coefficient
(p-value)
Income
regression coefficient
(p-value)
C. pneumoniae -0.919 (6.72 × 10
-4) 0.242 (0.023) -0.007 (0.021) 0.108 (0.095) 0.066 (0.238)
H. pylori -0.032 (0.832) 0.057 (0.454) -0.023 (4.49 × 10
-24) 0.135 (0.004) 0.120 (0.005)
T. gondii 0.000 (0.998) 0.106 (0.315) -0.022 (1.29 × 10
-13) 0.120 (0.054) 0.201 (6.61 × 10
-4)
CMV -0.291 (0.072) -0.181 (0.021) -0.031 (1.09 × 10
-38) -0.011 (0.809) 0.020 (0.647)
EBV -0.624 (3.89 × 10
-4) 0.151 (0.066) 0.001 (0.693) -0.002 (0.970) 0.034 (0.447)
HSV-1 -0.798 (4.37 × 10
-5) -0.008 (0.925) -0.009 (4.08 × 10
-4) 0.090 (0.084) 0.106 (0.029)
HSV-2 0.128 (0.350) -0.320 (2.19 × 10
-4) -0.018 (3.32 × 10
-13) 0.011 (0.822) 0.098 (0.033)
HHV-6 0.481 (8.97 × 10
-4) 0.194 (0.065) 0.021 (2.41 × 10
-13) -0.172(0.003) -0.118 (0.039)
VZV 0.230 (0.387) 0.150 (0.407) 0.000 (0.956) -0.071 (0.519) -0.181 (0.077)
Ad-36 -0.359 (0.011) -0.048 (0.607) 0.000 (0.991) 0.023 (0.671) 0.131 (0.010)
HAV -1.143 (2.29 × 10
-7) -0.024 (0.770) -0.038 (8.58 × 10
-46) 0.132 (0.014) 0.062 (0.179)
Influenza A 0.149 (0.412) 0.206 (0.045) -0.005 (0.117) -0.087 (0.154) -0.083 (0.143)
Influenza B 0.632 (4.52 × 10
-5) 0.128 (0.136) 0.003 (0.267) -0.075 (0.147) -0.014 (0.769)
All p-values in bold remain statistically significant after correcting for multiple testing across 13 pathogens using a conservative Sidàk correction.
* Analysis of location compares 147 individuals in Mexico with 1, 227 participants in the U.S. All remaining analyses presented in this table refer only to the 1,227
U.S. participants. Positive regression coefficient refers to higher seroprevalence in the U.S. compared to Mexico (e.g., HHV-6 seroprevalence is higher for U.S.
participants).
†Positive regression coefficient relates to a higher frequency in males compared to females (e.g., C. pneumoniae seroprevalence is higher in males).
Serostatus is a discrete trait, and since we used a liability threshold model for analysis of such dichotomous traits within a variance components model for
analysis of family data [29], the direction of effect of the predictor on the pathogen is opposite of the sign of the regression coefficient (e.g., H. pylori
seroprevalence decreases with higher education).
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Page 4 of 10observed for HSV-2, which was higher in women (25%)
than men (16%) (p = 2.2 × 10
-4, after adjusting for age
[Table 3]).
Figures 1 and 2 present the seroprevalence rates for all
participants across the age categories, using sliding 15-
year age windows to smooth the curves. Figure 1 includes
the herpesviruses, and Figure 2 includes all other agents
examined. Rates for males and females were combined
for each pathogen, except for HSV-2. Most pathogens
significantly increased in seroprevalence with age, as
expected, since there would be a greater opportunity for
exposure with age. For example, the rate of seropositivity
for H. pylori increased from ~40% at age 20 years, to
~80% by the age of 70 years (p = 4.5 × 10
-24). The sero-
prevalence of some of the pathogens, such as VZV,
remained relatively stable across the age groups, with
most individuals having acquired infection during child-
hood. HHV-6 is the only pathogen that showed a signifi-
cant decrease in seroprevalence by age (p = 2.4 × 10
-13).
It is noteworthy that antibody concentrations for some
pathogens tended to decline slightly in the oldest age
groups, possibly due to the impact of aging on the
immune system.
Education and income were also tested as potentially
contributing to seroprevalence of the pathogens exam-
ined in this study (Table 3). After accounting for sex and
age effects as well as multiple testing, a higher level of
education was a significant predictor (p = 0.003) of an
increased HHV-6 seropositivity rate, but a lower H. pylori
seroprevalence (p = 0.004). Higher household income
was significantly related to lower seroprevalence esti-
mates of T. gondii (p = 6.6 × 10
-4).
We also assessed serological evidence of exposure to
multiple pathogens. As demonstrated in Figure 3, all
study participants were seroreactive to at least 2 of 13
pathogens examined. The majority of participants (77%)
were seroreactive to 6 to 9 of the infections tested, with a
single subject showing seropositivity to all 13 of the
pathogens. On average, participants were seropositive to
8 of the pathogens examined.
Discussion
Comparing seroprevalence across studies is fraught with
difficulty because assays may vary, and modest changes in
antibody titer thresholds for defining serostatus categories
(positive, indeterminate, or negative) can have substantial
impacts on the estimated seroprevalence. These issues are
less of a concern for examining seroprevalence within a
single study, which is why we have focused our examina-
tion on the influence of sex, age, and other factors within
this Mexican American population. Nonetheless, a brief
comparison to published seroprevalence data is provided
(Table 4). Where possible, we used for comparison data
derived from the National Health and Nutrition
Figure 1 Seroprevalence of human herpesviruses by age (sliding 15-year age windows used to smooth the curves, and age shown is
the midpoint of each age interval).
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tative survey of the U.S. population that contains data on
minority populations, including Mexican Americans, and
covers the time period 1988 to 1994, which overlaps with
this study (1991-1995). Although routine childhood vacci-
nations against two pathogens (VZV and HAV) were
implemented in the U.S. in 1995, it does not affect the
results of this study or NHANES III, as both sets of data
Figure 2 Seroprevalence of miscellaneous pathogens by age (sliding 15-year age windows used to smooth the curves, and age shown
is the midpoint of each age interval.)
Figure 3 Number of seropositive reactions to infectious agents for each study participant.
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Page 6 of 10were collected during the pre-vaccine period. While the
data presented in this study may be considered “historical”
in that they were collected 15- 20 years ago, they are cru-
cial for investigating the relationship between infections
due to common pathogens and chronic diseases of aging.
In addition, they serve as a reference for studies investigat-
ing epidemiological changes that may have occurred over
time. Although every population is different, in one of our
own studies of Alaskan Natives [31] we found that sero-
prevalence rates, including for some of the same patho-
gens investigated here, have remained relatively stable
over time in that population.
Many of the pathogens quantified in this study exhibit
seroprevalence estimates similar to published reports of
Mexican Americans or the general U.S. population (Table
4). These include the herpesviruses HHV-6 and VZV.
Pathogens with seroprevalence rates similar to other Mexi-
can Americans, but higher than non-Hispanic Whites,
include HAV, H. pylori, and HSV-1. CMV and HSV-2 ser-
oprevalence rates are similar to previous data for non-His-
panic Whites and are lower than other Mexican American
populations. C. pneumoniae seroprevalence in this study
( 8 6 % )i se l e v a t e dc o m p a r e dt om o s tp u b l i s h e dl i t e r a t u r e
reports (e.g., 63% for Brooklyn, NY) [32]. In contrast,
T. gondii seroprevalence among study participants (9%) is
substantially lower than that observed in Mexican Ameri-
cans (25%) from one recent published study of NHANES
III sera [33].
The seroprevalence of EBV reported in this study (mini-
mum 47%, maximum 70% including indeterminates) is
somewhat lower than seroprevalence rates reported in
other adult populations [34]. It should be noted that this
estimate was published in 1969, which is much earlier
than the present study. In addition, other seroepidemiolo-
gic studies have typically measured IgG antibodies to EBV
viral capsid antigen (VCA), whereas an EBNA IgG assay
was utilized in our study. Although most EBV-infected
adults are both EBNA IgG and VCA IgG seropositive,
some persons do not generate an EBNA response, and
o t h e r sm a yl o s ea n t i b o d yt i t ers over time (especially
immunocompromised populations) [35]. EBV seropreva-
lence may also be related to the particular anti-EBNA IgG
ELISA test utilized for this study, and the cut-off values
established. A seropositivity rate similar to ours, using the
Table 4 Seroprevalence comparisons with published studies
Pathogens Seroprevalence rates
for this study, %
Seroprevalence
rates for comparative studies, %
(description of population)
C. pneumoniae 86 63 (Brooklyn, NY, USA) [32],
42 (Alaskan Natives) [31]
H. pylori 57 62 (Mexican American)* [62],
26 (non-Hispanic White)* [62]
T. gondii 9 25 (Mexican American)* [33],
24 (non-Hispanic White)* [33],
25 (general U.S. population)* [33]
CMV 55 85 (Mexican American)* [6],
57 (non-Hispanic White)* [6],
62 (general U.S. population)* [6]
EBV 46 73-90 (general U.S. adult population) [34]
HSV-1 82 88 (Mexican American)* [6],
65 (non-Hispanic White)* [6],
68 (general U.S. population)* [6]
HSV-2 22 (total)
25 (women)
16 (men)
38 (Mexican American women)* [33],
27 (Mexican American men)* [33],
65 (non-Hispanic Black women)* [33],
43 (non-Hispanic Black men)* [33],
22 (non-Hispanic White women)* [33],
18 (non-Hispanic White men)* [33],
25 (general U.S. population)* [33]
HHV-6 82 60-70 [63];
66-94 [4]
VZV 92 97(Mexican American)* [64],
97 (non-Hispanic White)* [64],
96 (general U.S. population)* [64]
Ad-36 13 11 (non-obese) [36],
30 (obese) [36]
HAV 73 82 (Mexican American)* [33],
29 (non-Hispanic White)* [33]
* NHANES III data
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Page 7 of 10same EBNA ELISA assay, was recently noted in another
adult U.S. population (R. Yolken, data not shown).
Data are accumulating from several groups from Italy,
Korea and the U.S. for the possible role of Ad-36 in contri-
buting to obesity in humans [36-39]; however, one U.S.
study did not find an association of Ad-36 with human
obesity [40]. In this first study to characterize Ad-36 sero-
prevalence in a Hispanic population, the 13% infection
rate observed for Ad-36 in these subjects was lower than
the 30% rate observed in obese non-Hispanic subjects
reported earlier [36], despite substantial rates of obesity
among study participants (39% obese, mean BMI of 29). It
should also be noted, however, that there are differences
in the timing of sample collection between the two studies,
as the samples used in the other study were collected
more recently.
T h es e r o p r e v a l e n c er a t e sf o ri n f l u e n z aAa n dBp r e -
sented in this study (77% and 58%, respectively) are based
on whole virus assays that do not distinguish between
naturally acquired antibodies and those resulting from sea-
sonal vaccinations (which typically include two A and one
B influenza virus strains). These data were not comparable
to type-specific assays, and therefore were not included in
the comparisons presented in Table 4.
Approximately half of the pathogens exhibited signifi-
cant differences in sex- and age-adjusted seroprevalence
by location of residence. Pathogens C. pneumoniae, EBV,
HSV-1, and HAV were significantly higher in seropreva-
lence in subjects from Mexico. Several of these agents
(e.g., C .p n e u m o n i a e ,H .p y l o r i ,H S V - 1 ,a n dH A V )a r e
known to be associated with lower socioeconomic status,
crowded conditions, or residence in a developing country
[41-46,32]. Two pathogens, HHV-6 and influenza B,
exhibited higher seroprevalence among individuals located
in the U.S. HHV-6 seropositivity was also associated with
higher education. Higher rates of influenza B may be due
to increased seasonal flu vaccination rates among indivi-
duals residing in the U.S., or higher circulation of influ-
enza B in the U.S. during preceding years.
The only pathogen in this study for which there was a
statistically significant difference in seroprevalence rates
between the sexes was HSV-2, at 25% in women and 16%
in men. Higher rates of HSV-2 seroprevalence in women
have been reported worldwide, as summarized previously
[45], and are attributable to a higher risk of acquisition of
this sexually transmitted pathogen in women.
The significant increase in seroprevalence rates by age
for six of the 13 pathogens (H. pylori, T. gondii, CMV,
HSV-1, HSV-2, and HAV) is likely the result of more
opportunities for exposure as a person ages. For the her-
pesviruses this may also be due to a reactivation of the
virus after a period of latency, and for T. gondii, this could
occur from the activation of relatively slow growing organ-
isms in tissue cysts. However, our observed increase in
seroprevalence rates with age may also be due to a cohort
effect wherein pathogen exposure was more frequent
among individuals belonging to the older age groups. This
is supported by evidence for a trend toward decreased
HAV, HSV-1 and HSV-2 seroprevalence rates in the U.S.,
probably resulting from improved hygiene and sanitation,
or changes in sexual practices [43,46]. Among participants
of this study, HHV-6 was the only pathogen that
decreased significantly with age. Previous studies indicate
that HHV-6 seroprevalence rates peak in early childhood,
at approximately three years of age, followed by a decline
in antibody titer thereafter [47]. Among adults, continued
decline in antibody titer with age indicates that HHV-6
reinfection or reactivation is rare [48].
In this study the effects of socioeconomic factors,
including education and income, were assessed to deter-
mine their effect on pathogen serostatus. The enteric
pathogen H. pylori showed a significant decline in seropre-
v a l e n c er a t ea s s o c i a t e dw i t hh igher level of educational
achievement, likely related to better hygiene and sanita-
tion, and perhaps also to less household crowding and
smaller family size. Seropositivity for HHV-6, on the other
hand, increased significantly with more education. Given
that this pathogen is typically acquired during early child-
hood, this higher seroprevalence rate may be related to
activities promoting transmission that are utilized more
frequently in those with higher education (e.g. day care).
T. gondii exhibited a significant decline in seropositivity
related to increased household income. Differences in
culinary practices (e.g. avoidance of raw or undercooked
meat) and/or hygiene (e.g. avoidance of food, water, and
soil contaminated by shed oocytes from cat feces) likely
contribute to lower T. gondii seroprevalence [49].
Conclusions
This study examined the seroprevalence rates of 13 com-
mon infectious pathogens in a geographically defined
group of Mexican Americans from San Antonio, Texas,
who suffer from substantial rates of obesity, type 2 dia-
betes, cardiovascular risk factors, and other chronic dis-
e a s e[ 2 4 , 5 0 - 5 3 ] .T h es t u d yp o p u l a t i o nm a ya l s ob ea t
elevated risk for many infections associated with poor
hygienic conditions and crowding, given the modest aver-
age socioeconomic status of the study participants. Our
seroprevalence data for many of the pathogens is consis-
tent with this hypothesis. Of the pathogens prevalent in
this group, H. pylori, C. pneumoniae, HSV-1, HAV, and
CMV have all been linked to chronic illness, including car-
diovascular disease [54-59]. Studies also indicate that mul-
tiple infections may increase the risk of infection with
additional pathogens, increase the severity of the other
infections, or both [60,61,6]. The assessment of serological
evidence of exposure to multiple pathogens demonstrates
that the Mexican American participants in this study have
Rubicz et al. BMC Research Notes 2011, 4:433
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Page 8 of 10serological evidence of exposure to a number of different
pathogens, potentially influencing health and contributing
to the development of chronic disease in this population
from San Antonio, Texas.
Additional material
Additional File 1: Seroprevalence estimates for participants residing
in Mexico. Table containing seroprevalence estimates by sex for the 13
pathogens examined in this study for 147 individuals residing in Mexico.
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